Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ]: Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
Thu, September 2, 2010
Wed, September 1, 2010
Tue, August 31, 2010
Mon, August 30, 2010
Sun, August 29, 2010
Fri, August 27, 2010
[ Fri, Aug 27th 2010 ]: Market Wire
?????????????????????
Thu, August 26, 2010
Wed, August 25, 2010
Tue, August 24, 2010
Mon, August 23, 2010
Fri, August 20, 2010
Thu, August 19, 2010
Wed, August 18, 2010

AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. -at-several-upcoming-investment-conferences.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the companya™s management will present at several upcoming investment conferences.

Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the following events:

  • Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 3:55 p.m. (EDT) at the Grand Hyatt in New York City.
  • UBS Global Life Sciences Conference on Monday, September 20, 2010 at 10:00 a.m. (EDT) at the Grand Hyatt in New York City.

David Johnston, chief financial officer, is scheduled to present at the following event:

  • JMP Securities Fifth Annual Healthcare Conference on Monday, September 27, 2010 at 3:30 p.m. (EDT) at the Palace Hotel in New York City.

AVEOa™s presentations will be webcast live and can be accessed by visiting the investors section of the companya™s website at [ www.investor.aveopharma.com ]. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].